Scilex Holding Company Accounts Payable and Other Accrued Liabilities
Scilex Holding Company (SCLX) had Accounts Payable and Other Accrued Liabilities of $3.37 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Liabilities › Accounts Payable and Accrued Liabilities
us-gaap:AccountsPayableAndOtherAccruedLiabilities · last filed 2026-08-14
- 2026-06-30: Accounts Payable and Other Accrued Liabilities $3.37M.
- 2026-03-31: Accounts Payable and Other Accrued Liabilities $2.46M.
- 2025-12-31: Accounts Payable and Other Accrued Liabilities $2.09M.
- 2025-09-30: Accounts Payable and Other Accrued Liabilities $35.00K.
| Period end | Accounts Payable and Other Accrued Liabilities | Accounts Payable and Other Accrued Liabilities as first filed |
|---|---|---|
| 2026-06-30 | $3.37M 10-Q · filed 2026-08-14 | |
| 2026-03-31 | $2.46M 10-Q · filed 2026-05-20 | |
| 2025-12-31 | $2.09M 10-Q · filed 2026-08-14 | |
| 2025-09-30 | $35.00K 10-Q · filed 2025-11-14 | |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-13 | |
| 2025-03-31 | $147.00K 10-Q · filed 2025-05-14 | |
| 2024-12-31 | $107.00K 10-K · filed 2026-04-10 | |
| 2024-09-30 | $346.00K 10-Q · filed 2025-01-17 | |
| 2024-06-30 | $303.00K 10-Q · filed 2024-08-13 | |
| 2024-03-31 | $354.00K 10-Q · filed 2024-05-13 | |
| 2023-12-31 | $280.00K 10-K · filed 2025-03-31 | $780.00K 10-K · filed 2024-03-12 |
| 2023-09-30 | $2.04M 10-Q · filed 2023-11-14 | |
| 2023-06-30 | $78.00K 10-Q · filed 2023-08-11 | |
| 2023-03-31 | $960.00K 10-Q · filed 2023-05-12 | |
| 2022-12-31 | $79.00K 10-K · filed 2024-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |